Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Afimoxifene |
Synonyms | |
Therapy Description |
Afimoxifene (4-hydroxy-tamoxifen) is a metabolite of tamoxifen, which binds to the estrogen receptor and acts as an antagonist in tumor cells (PMID: 32019136). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Afimoxifene | 4-Hydroxy-Tamoxifen|4-hydroxytamoxifen|Hydroxytamoxifen | Hormone - Anti-estrogens 29 | Afimoxifene (4-hydroxy-tamoxifen) is a metabolite of tamoxifen, which binds to the estrogen receptor and acts as an antagonist in tumor cells (PMID: 32019136). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04009044 | Phase II | Afimoxifene | Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast | Recruiting | USA | 0 |
NCT02993159 | Phase II | Afimoxifene Tamoxifen | Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast | Recruiting | USA | 0 |